Factors influencing the willingness of US women to vaccinate their daughters against the human papillomavirus to prevent cervical cancer

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Lai, Jennifer Y ^a   Tinker, Anna V ^a   Cheung, Winson Y ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

HPV knowledge; HPV vaccine; US women

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; ARTICLE; CAUCASIAN; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; ADOLESCENT; ANALYSIS OF VARIANCE; ATTITUDE TO HEALTH; CHI SQUARE DISTRIBUTION; MIDDLE AGED; MOTHER; NUCLEAR FAMILY; PAPILLOMAVIRUS INFECTION; PATIENT PARTICIPATION; PSYCHOLOGICAL ASPECT; SOCIOECONOMICS; UTERINE CERVIX TUMOR; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MIDDLE AGED; MOTHERS; NUCLEAR FAMILY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT PARTICIPATION; QUESTIONNAIRES; SOCIOECONOMIC FACTORS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84876282593     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0582-z     Document Type: Article

References (45)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. SEER Cancer Statistics Review (1975-2007) National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010: 2010. http://seer.cancer. gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
3. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA. 1983;80:3812-5.
4. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984;3:1151-7.
5. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796-802.
6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9.
7. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27.
8. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98:303-15.
9. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.
10. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-9.
11. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-32.
12. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185:251-7.
13. Ghim SJ, Jenson AB, Schlegel R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology. 1992;190:548-52.
14. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol. 1993;67:1936-44.
15. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-43.
16. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.
17. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-70.
18. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298:743-53.
19. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States. Adv Data. 2002;2005:1-55.
20. Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health. 2007;40:108-15.
21. Bernat DH, Harpin SB, Eisenberg ME, Bearinger LH, Resnick MD. Parental support for the human papillomavirus vaccine. J Adolesc Health. 2009;45:525-7.
22. Dempsey AF, Abraham LM, Dalton V, Ruffin M. Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol. 2009;19:531-8.
23. Jain N, Stokley S, Yankey MA. Centers for disease control and prevention. Vaccination coverage among adolescents aged 13-17 years-United States, 2007. MMWR2008:1100-1103.
24. Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine. 2009.
25. Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health. 2009;45:453-62.
26. Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol. 2010;171:357-67.
27. Gerend MA, Weibley E, Bland H. Parental response to human papillomavirus vaccine availability: uptake and intentions. J Adolesc Health. 2009;45:528-31.
28. Cantor DCK, Crystal-Mansour S, Davis T, Dipko S, Sigman R.: Health Information National Trends Survey (HINTS) 2007 Final Report. In: Rockville M, editor. Westat2009.
29. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med. 2007;45:107-14.
30. Holcomb B, Bailey JM, Crawford K, Ruffin MTt. Adults' knowledge and behaviors related to human papillomavirus infection. J Am Board Fam Pract. 2004;17:26-31.
31. Behbakht K, Lynch A, Teal S, Degeest K, Massad S. Social and cultural barriers to Papanicolaou test screening in an urban population. Obstet Gynecol. 2004;104:1355-61.
32. Tiro JA, Meissner HI, Kobrin S, Chollette V. What do women in the US know about human papillomavirus and cervical cancer? Cancer Epidemiol Biomarkers Prev. 2007;16:288-94.
33. Brownson RC, Jackson-Thompson J, Wilkerson JC, Davis JR, Owens NW, Fisher EB Jr. Demographic and socioeconomic differences in beliefs about the health effects of smoking. Am J Public Health. 1992;82:99-103.
34. Manderbacka K, Lundberg O, Martikainen P. Do risk factors and health behaviours contribute to self-ratings of health? Soc Sci Med. 1999;48:1713-20.
35. Wynd CA. Smoking patterns, beliefs, and the practice of healthy behaviors in abstinent, relapsed, and recalcitrant smokers. J Vasc Nurs. 2007;25:32-8.
36. Boehner CW, Howe SR, Bernstein DI, Rosenthal SL. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis. 2003;30:774-8.
37. Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis. 2004;8:188-94.
38. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS. 2003;14:300-6.
39. Lemon SC, Rakowski W, Clark MA, Roy J, Friedmann PD. Variations in influenza vaccination among the elderly. Am J Health Behav. 2004;28:352-60.
40. Hoover DR, Sambamoorthi U, Crystal S. Characteristics of community dwelling elderly not vaccinated for pneumococcus in 1998 and 2001. Prev Med. 2004;39:517-27.
41. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among persons aged >or =65 years-United States, 2001. JAMA. 2002;288:2815-7.
42. Chen JY, Fox SA, Cantrell CH, Stockdale SE, Kagawa-Singer M. Health disparities and prevention: racial/ethnic barriers to flu vaccinations. J Community Health. 2007;32:5-20.
43. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006;117:1486-93.
44. Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health. 2005;37:248-51.
45. Gamble HL, Klosky JL, Parra GR, Randolph ME: Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol. 2009.